| Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ... Science 364 (6439), 485-491, 2019 | 464 | 2019 |
| Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen–specific T-cell immunity in head and neck cancer patients RM Srivastava, SC Lee, PA Andrade Filho, CA Lord, HB Jie, HC Davidson, ... Clinical Cancer Research 19 (7), 1858-1872, 2013 | 356 | 2013 |
| Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer F Concha-Benavente, RM Srivastava, S Trivedi, Y Lei, U Chandran, ... Cancer research 76 (5), 1031-1043, 2016 | 333 | 2016 |
| Immunogenic neoantigens derived from gene fusions stimulate T cell responses W Yang, KW Lee, RM Srivastava, F Kuo, C Krishna, D Chowell, ... Nature medicine 25 (5), 767-775, 2019 | 320 | 2019 |
| Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients HB Jie, N Gildener-Leapman, J Li, RM Srivastava, SP Gibson, ... British journal of cancer 109 (10), 2629-2635, 2013 | 309 | 2013 |
| Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer G Shayan, R Srivastava, J Li, N Schmitt, LP Kane, RL Ferris Oncoimmunology 6 (1), e1261779, 2017 | 286 | 2017 |
| Immunomodulatory and therapeutic activity of curcumin RM Srivastava, S Singh, SK Dubey, K Misra, A Khar International immunopharmacology 11 (3), 331-341, 2011 | 278 | 2011 |
| CTLA-4+ Regulatory T Cells are Increased in Cetuximab Treated Head and Neck Cancer Patients, Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis FRL Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S ... Cancer Research, 2015 | 273* | 2015 |
| Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy C Krishna, RG DiNatale, F Kuo, RM Srivastava, L Vuong, D Chowell, ... Cancer cell 39 (5), 662-677. e6, 2021 | 222 | 2021 |
| PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer BA Kansy, F Concha-Benavente, RM Srivastava, HB Jie, G Shayan, Y Lei, ... Cancer research 77 (22), 6353-6364, 2017 | 203 | 2017 |
| Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity SC Lee, RM Srivastava, A López-Albaitero, S Ferrone, RL Ferris Immunologic research 50, 248-254, 2011 | 188 | 2011 |
| Immunomodulatory effects of curcumin: in-vivo CH Varalakshmi, AM Ali, BVV Pardhasaradhi, RM Srivastava, S Singh, ... International immunopharmacology 8 (5), 688-700, 2008 | 169 | 2008 |
| Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients S Trivedi, RM Srivastava, F Concha-Benavente, S Ferrone, ... Clinical Cancer Research 22 (21), 5229-5237, 2016 | 158 | 2016 |
| Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy RM Samstein, C Krishna, X Ma, X Pei, KW Lee, V Makarov, F Kuo, ... Nature Cancer 1 (12), 1188-1203, 2020 | 142 | 2020 |
| CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer RM Srivastava, S Trivedi, F Concha-Benavente, SP Gibson, C Reeder, ... Clinical Cancer Research 23 (3), 707-716, 2017 | 126 | 2017 |
| Commensal bacteria stimulate antitumor responses via T cell cross-reactivity CA Bessell, A Isser, JJ Havel, S Lee, DR Bell, JW Hickey, ... JCI insight 5 (8), 2020 | 119 | 2020 |
| Cell-Selective Lysis by Novel Analogues of Melittin against Human Red Blood Cells and Escherichia coli BK Pandey, A Ahmad, N Asthana, S Azmi, RM Srivastava, S Srivastava, ... Biochemistry 49 (36), 7920-7929, 2010 | 113 | 2010 |
| Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma M Kikuchi, DA Clump, RM Srivastava, L Sun, D Zeng, JA Diaz-Perez, ... Oncoimmunology 6 (7), e1329071, 2017 | 104 | 2017 |
| Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients HB Jie, RM Srivastava, A Argiris, JE Bauman, LP Kane, RL Ferris Cancer immunology research 5 (5), 408-416, 2017 | 103 | 2017 |
| Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients Z Liu, EL McMichael, G Shayan, J Li, K Chen, R Srivastava, LP Kane, ... Clinical Cancer Research 24 (18), 4529-4538, 2018 | 96 | 2018 |
Robert L. FerrisUniversity of Pittsburgh在 upmc.edu 的电子邮件经过验证
